MRUS241220C30000
- 17.90
- 0.000.00%
Merus Newsroom
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Merus(MRUS.US) With Buy Rating
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $85 to $100
TD Cowen Remains a Buy on Merus (MRUS)
Truist Financial Issues a Buy Rating on Merus (MRUS)
Merus Analyst Ratings
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Buy Rating for Merus: Promising Pipeline and Competitive Advantage of Petosemtamab
Goldman Sachs Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Truist Financial Initiates Merus(MRUS.US) With Buy Rating
Merus Price Target Maintained With a $85.00/Share by Needham
Merus Analyst Ratings
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
Merus's Promising Pipeline and Financial Strength Support Buy Rating
H.C. Wainwright Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Truist Financial Maintains Merus(MRUS.US) With Buy Rating